Literature DB >> 11703373

Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

E C Darcissac1, V Vidal, X De La Tribonniere, Y Mouton, G M Bahr.   

Abstract

Serum levels of interleukin-7 (IL-7), a non-redundant cytokine that plays a crucial role in lymphopoiesis, are known to be elevated in HIV-1-infected subjects. To examine further the association between levels of IL-7, CD4+ cell counts and viraemia, we analysed these parameters in a large cohort of HIV-1 patients along with serum levels of 90K, a marker of disease severity but with no established involvement in lymphopoiesis. While IL-7 levels were only found to correlate with CD4+ cell counts, 90K levels presented strong correlations with both CD4+ cell numbers and with plasma viral loads (VLs). These correlations were maintained in patients naive to treatment with antiretrovirals (n = 38) but were abolished when the analysis was restricted to the group receiving highly active antiretroviral therapy (HAART, n = 82). Moreover, although 90K levels were significantly reduced in patients on HAART, IL-7 levels continued to be elevated despite successful treatment. The influence of HAART on the variations in these serum parameters was further assessed in a longitudinal study on 32 subjects. The HAART-induced decrease in VLs and increase in CD4+ counts were found to correlate with a reduced serum level of 90K and IL-7, respectively. Nevertheless, following a median period of 33 months of immunological and virological successful HAART, serum levels of IL-7 continued to be significantly elevated compared with those detected in healthy controls. These findings suggest that immunotherapy with IL-7, aimed to replenish T-cell stock in HAART-treated subjects, may have a limited impact on the process of immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703373      PMCID: PMC1906202          DOI: 10.1046/j.1365-2249.2001.01670.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  The secreted tumor-associated antigen 90K is a potent immune stimulator.

Authors:  A Ullrich; I Sures; M D'Egidio; B Jallal; T J Powell; R Herbst; A Dreps; M Azam; M Rubinstein; C Natoli
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

Review 2.  The immunopathology of HIV infection.

Authors:  C A Andrews; R A Koup
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

3.  Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection.

Authors:  L Gattegno; M Bentata-Peyssare; S Gronowski; K Chaouche; F Ferriere
Journal:  Cell Adhes Commun       Date:  1995-08

Review 4.  Immunological and virological markers of HIV-disease progression.

Authors:  J M Zeller; N L McCain; B Swanson
Journal:  J Assoc Nurses AIDS Care       Date:  1996 Jan-Feb       Impact factor: 1.354

5.  90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection.

Authors:  C Natoli; F Dianzani; F Mazzotta; E Balocchini; P Pierotti; G Antonelli; S Iacobelli
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-04

6.  A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men.

Authors:  N C Briggs; C Natoli; N Tinari; M D'Egidio; J J Goedert; S Iacobelli
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

7.  A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

Authors:  T J Powell; R Schreck; M McCall; T Hui; A Rice; H App; M Azam; A Ullrich; L K Shawver
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-05

8.  The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection.

Authors:  S Iacobelli; A Ullrich; N Tinari; L Ortona; E Tamburrini; M D'Egidio; F Ghinelli; L Sighinolfi; M Piazza; A Chirianni
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-12-01

9.  Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users.

Authors:  C Casoli; A Lisa; G Magnani; R Starcich; F Fiaccadori; U Bertazzoni; G Zei
Journal:  J Med Virol       Date:  1995-02       Impact factor: 2.327

10.  Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine.

Authors:  U von Freeden-Jeffry; P Vieira; L A Lucian; T McNeil; S E Burdach; R Murray
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  9 in total

1.  Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Authors:  Jessica N Hodge; Sharat Srinivasula; Zonghui Hu; Sarah W Read; Brian O Porter; Insook Kim; Joann M Mican; Chang Paik; Paula Degrange; Michele Di Mascio; Irini Sereti
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

2.  Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children.

Authors:  Rafael Correa; Salvador Resino; M Angeles Muñoz-Fernández
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

3.  Increased thymic output during acute measles virus infection.

Authors:  Sallie R Permar; William J Moss; Judith J Ryon; Daniel C Douek; Mwaka Monze; Diane E Griffin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Preserved immune system in long-term asymptomatic vertically HIV-1 infected children.

Authors:  S Resino; R Correa; J M Bellón; M A Muñoz-Fernández
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

5.  Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

Authors:  Susannah Ellsworth; Ani Balmanoukian; Ferdynand Kos; Christopher J Nirschl; Thomas R Nirschl; Stuart A Grossman; Leo Luznik; Charles G Drake
Journal:  Oncoimmunology       Date:  2014-01-03       Impact factor: 8.110

Review 6.  HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion.

Authors:  Saina Beitari; Yimeng Wang; Shan-Lu Liu; Chen Liang
Journal:  Viruses       Date:  2019-03-30       Impact factor: 5.048

7.  Galectin 3-binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein.

Authors:  Tsuneyoshi Seki; Motoi Kanagawa; Kazuhiro Kobayashi; Hisatomo Kowa; Naoki Yahata; Kei Maruyama; Nobuhisa Iwata; Haruhisa Inoue; Tatsushi Toda
Journal:  J Biol Chem       Date:  2020-01-29       Impact factor: 5.157

8.  Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis.

Authors:  Rungnapa Pankla; Surachat Buddhisa; Matthew Berry; Derek M Blankenship; Gregory J Bancroft; Jacques Banchereau; Ganjana Lertmemongkolchai; Damien Chaussabel
Journal:  Genome Biol       Date:  2009-11-10       Impact factor: 13.583

9.  M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner.

Authors:  Qin Wang; Xiaolin Zhang; Yuling Han; Xinlu Wang; Guangxia Gao
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.